Monitor for future share sales under the equity line, which could cause significant dilution. The company's shift to biopharma is high-risk but could be transformative if Entolimod succeeds. The going concern opinion from auditors suggests liquidity risk.
Executive Summary
Tivic Health Systems is registering 956,222 shares for resale by Tumim Stone Capital, a private investor, under a $50 million equity line agreement. The company is transitioning from consumer healthtech to a biopharma focus on Entolimod, a late-stage TLR5 agonist for acute radiation syndrome and oncology. Tivic will receive proceeds from future stock sales to Tumim, but not from this resale registration.
Key Facts
- Company is transitioning from consumer healthtech to biopharma, focusing on Entolimod for acute radiation syndrome and oncology indications
- Tivic entered into a $50 million equity line agreement with Tumim Stone Capital, allowing it to sell shares over 24 months
- This filing registers 956,222 shares for resale by Tumim, consisting of 519,210 shares Tivic may sell and 437,012 shares from a pre-funded warrant
- Tivic received $300,000 cash and issued 945,785 shares plus preferred stock to Statera Biopharma for the Entolimod license
- The company incurred $347,000 in charges to wind down its consumer ClearUP business
- Tivic launched Velocity Bioworks, a CDMO subsidiary, in December 2025 to support manufacturing
- Financial statements show substantial doubt about the company's ability to continue as a going concern
Financial Impact
Tivic may receive up to $50 million from future stock sales to Tumim under the equity line agreement
Risk Factors
- Substantial dilution from the equity line and potential future offerings
- Going concern uncertainty as noted by auditors
- Execution risk in transitioning from consumer healthtech to biopharma
- Dependence on Entolimod's clinical and regulatory success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001683168-26-002867 |
| Document: tivic_ex107.htm | 0001683168-26-002867 |
| Document: tivic_ex0501.htm | 0001683168-26-002867 |
| Document: tivic_ex2301.htm | 0001683168-26-002867 |
| Document: 0001683168-26-002867-index-headers.html | 0001683168-26-002867 |
| Document: 0001683168-26-002867-index.html | 0001683168-26-002867 |
| Document: 0001683168-26-002867.txt | 0001683168-26-002867 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers